Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Trevi Therapeutics鈥� dense biotech disclosures to find the next Haduvio milestone or dilution risk can feel like reading lab notes in a foreign language. Clinical-stage companies report reams of trial data, patent updates, and stock offering details鈥攜et investors still need one clear answer: how does it affect TRVI鈥檚 value?
Stock Titan鈥檚 AI-powered analysis turns Trevi Therapeutics SEC filings into plain English. Whether you鈥檙e tracking a sudden 8-K material event explained, scanning the latest Trevi Therapeutics quarterly earnings report 10-Q filing, or comparing insider moves, our platform highlights what matters. AG真人官方-time alerts surface Trevi Therapeutics Form 4 insider transactions real-time, while concise summaries break down R&D spend, trial endpoints, and cash runway in the annual report鈥攖hink Trevi Therapeutics annual report 10-K simplified rather than 200 pages of jargon.
Common questions are answered as you read: 鈥淲hy did management sell shares?鈥濃�攃heck the Trevi Therapeutics executive stock transactions Form 4. 鈥淒id the proxy reveal new stock-option grants?鈥濃�攕ee the Trevi Therapeutics proxy statement executive compensation. Need quick context before a catalyst? Our dashboards pair AI text extraction with key metrics so understanding Trevi Therapeutics SEC documents with AI becomes part of your workflow. From Trevi Therapeutics insider trading Form 4 transactions to Trevi Therapeutics earnings report filing analysis, every disclosure is searchable, linked, and explained simply鈥攕aving hours and giving you the clarity to act before the market does.
Trevi Therapeutics (TRVI) filed a Form 144 reporting a proposed sale of common stock through Stifel Nicolaus & Company. The notice lists 312,855 shares to be sold with an aggregate market value of $2,532,530, against total shares outstanding of 121,776,855. The approximate date of sale is 08/27/2025 and the securities exchange is Nasdaq.
The filing discloses how the shares were acquired: 65,712 shares from restricted stock units dated 02/15/2023 (paid 02/16/2023 in cash) and 259,576 shares from an option exercise dated 02/26/2023 (paid 02/16/2023 in cash). No securities were reported sold by the person in the past three months. The filer signs the standard representation that they do not possess nonpublic material adverse information about the issuer.
Viking Global Investors and affiliated entities report beneficial ownership of 7,505,694 shares of Trevi Therapeutics (TRVI), representing 5.9% of the common stock. The holdings consist of 1,543,000 shares directly owned by two affiliated entities (1,033,810 by VGOP and 509,190 by VGOD) and 5,962,694 shares issuable upon exercise of pre-funded warrants exercisable at $0.001 per share. The filing clarifies the ownership chain through multiple Delaware and Cayman entities and notes shared voting and dispositive power among the reporting persons, including O. Andreas Halvorsen, David C. Ott and Rose S. Shabet. The statement affirms these securities were not acquired to change or influence control of the issuer.
NEA amendments report current holdings and a dilution-driven decrease in stake. The filing discloses that New Enterprise Associates and affiliated reporting persons collectively beneficially own 15,074,080 shares of Trevi Therapeutics common stock, representing 12.0% of the outstanding class on the basis stated in the filing. NEA 16 is shown as the record owner of 10,421,428 shares and as holding warrants exercisable for 3,703,704 shares; NEA 18 VGE holds 948,948 shares. The ownership figures reflect shared voting and dispositive power among the reporting entities and individuals.
The amendment explains the decrease in the percentage ownership as resulting from an increase in the number of shares outstanding, and reiterates that the Funds acquired the shares for investment purposes. The filing states there are no present plans by the reporting persons to pursue corporate actions such as board changes, asset sales, or extraordinary transactions, and notes that no transactions were effected by the reporting persons in the last 60 days. Exhibits include the joint filing agreement and a power of attorney.
FAQ
What is the current stock price of Trevi Therapeutics (TRVI)?
What is the market cap of Trevi Therapeutics (TRVI)?
